Molecular Partners AG (NASDAQ:MOLN - Get Free Report) traded up 0.3% on Thursday . The company traded as high as $4.85 and last traded at $4.88. 413 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 4,344 shares. The stock had previously closed at $4.87.
Molecular Partners Trading Down 7.0 %
The company has a 50-day moving average of $5.14 and a 200-day moving average of $5.41. The firm has a market capitalization of $188.90 million, a price-to-earnings ratio of -2.18 and a beta of 1.06.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Molecular Partners stock. BVF Inc. IL boosted its holdings in Molecular Partners AG (NASDAQ:MOLN - Free Report) by 205.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,353,968 shares of the company's stock after acquiring an additional 910,747 shares during the period. BVF Inc. IL owned about 3.35% of Molecular Partners worth $6,458,000 at the end of the most recent quarter. Institutional investors and hedge funds own 26.55% of the company's stock.
Molecular Partners Company Profile
(
Get Free Report)
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Featured Articles
Before you consider Molecular Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molecular Partners wasn't on the list.
While Molecular Partners currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
